1.. Introduction {#s5}
================

Individuals with schizophrenia need long-term or even lifelong treatment with antipsychotic medication.\[[@B1]\] Clozapine is a highly effective and safe antipsychotic medication widely used for the treatment of schizophrenia, particularly among patients for whom other antipsychotic medications are ineffective. However, common side-effects of the long-term use of clozapine are weight gain and obesity,\[[@B2],[@B3]\] problems that both lower patients\' medication compliance and increase the risk of metabolic syndrome, diabetes, hypertension, and coronary heart disease.\[[@B4],[@B5],[@B6]\] Recent studies in China and elsewhere have assessed the effectiveness of adjunctive treatment with metformin,\[[@B7],[@B8]\] memantine,\[[@B9]\] nizatidine,\[[@B10]\] and topiramate\[[@B11]\] to reduce or eliminate antipsychotic-induced weight gain and other metabolic changes in patients with schizophrenia. To our knowledge, there is no published meta-analysis on this issue that specifically focuses on clozapine-induced weight gain, so the present study identified randomized controlled trails (RCTs) published in English or Chinese about the adjunctive use of metformin to reduce clozapine-induced weight gain in adult patients with schizophrenia and then conducted a meta-analysis of the pooled results from these studies.

2.Methods {#s6}
=========

2.1 Search strategy {#s6a}
===================

We searched the following databases for studies published in English or Chinese prior to December 15, 2015: PubMed, PsycINFO, EBSCO, EMbase, Cochrane Library, China Academic Journals Full-text Database (CJFD), WANFANG DATA, Chongqing VIP database for Chinese Technical Periodicals, and Chinese Biomedical Literature (CBM) Database. We used the keywords \'clozapine,\' \'antipsychotics,\' \'metformin,\' \'body mass,\' \'body weight,\' \'BMI,\' \'RCT\', and \'randomized controlled trials\' (and the Chinese equivalents) in the searches. The search strategy and keywords were modified to meet the requirements of the different databases. Reference lists of identified articles were hand-searched to locate relevant articles that may not have been identified in the electronic searches.

2.2 Inclusion and exclusion criteria {#s6b}
====================================

Included studies were randomized controlled trials (RCTs) published in either Chinese or English among adult patients with schizophrenia being treated with monotherapy clozapine (i.e., not including concurrent treatment with other antipsychotic medications) that compared changes in body weight or changes in body mass index (BMI) in an intervention group of patients receiving clozapine plus adjunctive treatment with metformin versus changes in a control group that received clozapine with an adjunctive placebo or in a control group that received clozapine alone (with no adjunctive treatment). Observational studies, nonhuman studies, systematic reviews, research proposals, case reports, and duplicate reports were excluded. Research participants had to be 18-65 years of age and meet the diagnostic criteria for schizophrenia specified in the 2^nd^ or 3^rd^ version of the Chinese Classification of Mental Disorders (CCMD-2, CCMD-3),\[[@B12],[@B13]\] the 10^th^ revision of the International Classification of Diseases (ICD-10),\[[@B14]\] or the 4^th^ or 5^th^ edition of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association (DSM-IV, DSM-5).\[[@B15],[@B16]\]

2.3 Screening of articles and data extraction {#s6c}
=============================================

Two researchers (LZR and ZW) independently screened articles identified in the electronic databases using the inclusion criteria and abstracted information from selected articles. If they disagreed about the inclusion of an article or about abstracted data they jointly reviewed the article to identify the reason for the inconsistency and, if they could still not agree, they referred to a third author (GS) to make the final decision. Data extracted from the selected articles included year and language of the publication; location of the study; sample size, method of randomization, treatment in the control group, and duration of follow-up; dosage of clozapine and metformin; outcomes and side effects assessed; and methods for assessing these outcomes.

2.4 Evaluation of risk of bias {#s6d}
==============================

Two researchers (LZR and ZW) independently assessed the risk of bias for all included articles based on the Cochrane Risk of Bias (RoB) tool.\[[@B17]\] The items in this instrument are: (a) random assignment \'sequence generation\'; (b) \'allocation sequence concealment\'; (c) \'blinding of participants and personnel\'; (d) \'blinding of outcome assessment\'; (e) \'incomplete outcome data\'; (f) \'selective outcome reporting\'; and (g) \'other potential threats to validity\'. A third author\'s (GS) opinion was sought when the two researchers disagreed. If necessary, study author(s) were contacted via e-mail to supply missing information.

2.5 Outcome measures {#s6e}
====================

The main outcome measures were body weight in kilograms (kg) and body mass index (BMI, weight in kg divided by the square of height in meters). Secondary outcome measures included the treatment effect as evaluated by changes in the Brief Psychiatric Rating Scale (BPRS)\[[@B18]\] or the Positive and Negative Syndrome Scale (PANSS),\[[@B19]\] the dropout rate, and the prevalence of adverse events (which were based on patients\' reports of side effects and routine blood chemistry tests, urinalysis tests, and electrocardiograms).

2.6 Evaluation of the strength of evidence {#s6f}
==========================================

Two researchers (LZR and ZW) used the Cochrane Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) software\[[@B20]\] to evaluate the strength of evidence for each outcome measure of interest. Based on the study\'s design, the possibility of publication bias, indirect evidence, and the consistency, precision, and effect-size of the outcome measure, the level of evidence for each outcome was classified as \'high\',\'moderate\',\'low\', or \'very low\'.

2.7 Analysis {#s6g}
============

We used RevMan 5.3\[[@B21]\] to compute the mean difference (MD) and its 95% confidence interval (95% CI) for continuous outcomes (e.g., weight and BMI), the standardized mean difference (SMD) and its 95% CI for continuous measures assessed using different measures (e.g., treatment effect), and the risk ratio (RR) and its 95% CI for dichotomous outcomes (e.g., occurrence of each type of side effect). We assessed the *Q*-test and *I*^2^ to quantify heterogeneity:\[[@B22]\] if the p-value of the *Q*-test was \>0.10 and *I*^2^\<50%, this indicated that the study results were homogeneous and a fixed effect model was employed to meta-analyze the pooled sample; otherwise a random effects model was employed.\[[@B20]\] There were only 6 studies included in the meta-analysis, so it was not possible to assess publication bias (which requires a minimum of 10 studies\[[@B23]\]). All statistical tests were two-tailed and the level of statistical significance was set at *p*\<0.05.

3.Results {#s8}
=========

3.1. Characteristics of included studies {#s8a}
========================================

As shown in [Figure 1](#Figure1){ref-type="fig"}, we found 72 relevant articles in the various databases considered, 59 of which remained after removing papers that appeared in multiple databases. Six of these 59 studies met inclusion criteria;\[[@B7],[@B24],[@B25],[@B26],[@B27],[@B28]\] three published in English\[[@B7],[@B25],[@B27]\] and three published in Chinese.\[[@B25],[@B27],[@B28]\]

![Figure 1. Identification of included studies](sap-27-06-331-g003){#Figure1}

The characteristics of the six included studies are shown in [Table 1](#Table1){ref-type="table"} . The sample size ranged from 55 to 100 individuals with schizophrenia. The age and duration of illness of included patients varied considerably across studies. The oral dose of metformin used ranged from 250 to 1000 mg/d, and the duration of follow up ranged from 6 to 24 weeks. Three of the studies\[[@B7],[@B24],[@B26]\] provided clozapine plus an adjunctive placebo to patients in the control group; the other three studies\[[@B25],[@B27],[@B28]\] only provided clozapine to patients in the control group (i.e., without any adjunctive treatment).

###### 

Table 1. Characteristics of six randomized controlled trials included in the meta-analysis about adjunctive treatment of metformin for patients with schizophrenia being treated with clozapine

Table 1.

  ------------------------------------------------------------------------------------------------------------------------------------
  study                    diagnostic\   blind assessment\         sample\      mean\     mean duration\   metformin\   duration of\
                           criteria      /control group            size\        age\      of illness\      dosage\      follow-up\
                                                                   (males, %)   (years)   (years)          (mg/day)     (weeks)
  ------------------------ ------------- ------------------------- ------------ --------- ---------------- ------------ --------------
  Zhang 2004\[[@B28]\]     CCMD-2        not blinded\              60\          41        N/A              500          6
                                         no adjunctive treatment   (45%)                                                

  Carrizo 2009\[[@B7]\]    DSM-IV        double-blind\             61\          38.8      N/A              1000         14
                                         placebo-controlled        (N/A)                                                

  Liu 2012\[[@B25]\]       CCMD-3        not blinded\              100\         N/A       4.6              250-500      12
                                         no adjunctive treatment   (61%)                                                

  Chen 2013\[[@B24]\]      DSM-IV        double-blind\             55\          41.6      N/A              1500         24
                                         placebo-controlled        (51%)                                                

  Wu 2014\[[@B27]\]        CCMD-3        not blinded\              78\          26.5      1.8              1000         12
                                         no adjunctive treatment   (59%)                                                

  Hebrani 2015\[[@B26]\]   DSM-IV        double-blind\             60\          46.5      20.2             1000         20
                                         placebo-controlled        (46%)                                                
  ------------------------------------------------------------------------------------------------------------------------------------

3.2 Evaluation of the risk of bias {#s8b}
==================================

As shown in [Table 2](#Table2){ref-type="table"} , three of the studies were not blinded,\[[@B25],[@B27],[@B28]\] so patients, the clinicians, and the evaluators of the outcome measures were all aware of which patients were and were not receiving metformin, greatly increasing the risk of biased reporting of the results. The other three studies\[[@B7],[@B24],[@B26]\] blinded the patients, clinicians, and evaluators to the treatment group of the participants, but two of them\[[@B7],[@B26]\] did not indicate how blinding was maintained (i.e.,\'allocation sequence concealment\') and did not provide complete outcome data. Only one of the six studies\[[@B24]\] was classified as \'low risk of bias\' on all seven items in the Cochrane Risk of Bias (RoB) tool.\[[@B17]\]

###### 

Table 2. Evaluation of risk of bias in the six included studies based on the Cochrane Risk of Bias (ROB) tool\[[@B17]\]

Table 2.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  study                    sequence\    allocation sequence concealment   blinding of participants and personnel   blinding of outcome assessment   incomplete outcome data   selective outcome reporting   other potential threats to validity
                           generation                                                                                                                                                                       
  ------------------------ ------------ --------------------------------- ---------------------------------------- -------------------------------- ------------------------- ----------------------------- -------------------------------------
  Zhang 2004\[[@B28]\]     high         N/A                               high                                     high                             low                       low                           low

  Carrizo 2009\[[@B7]\]    low          N/A                               low                                      low                              high                      low                           low

  Liu 2012\[[@B25]\]       high         N/A                               high                                     high                             low                       low                           low

  Chen 2013\[[@B24]\]      low          low                               low                                      low                              low                       low                           low

  Wu 2014\[[@B27]\]        high         N/A                               high                                     high                             low                       low                           low

  Hebrani 2015\[[@B26]\]   low          N/A                               low                                      low                              high                      low                           low
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3.3 Meta-analysis results for changes in weight and BMI after adjunctive treatment with metformin {#s8c}
=================================================================================================

As shown in [Figure 2](#Figure2){ref-type="fig"}, five of the included studies with a pooled sample of 341 individuals compared changes in weight among adult patients with schizophrenia being treated with clozapine who were and were not treated with adjunctive metformin.\[[@B7],[@B24],[@B25],[@B27],[@B28]\] The results of the five studies were reasonably homogeneous (*I*^2^=40%, *p*=0.16), so a fixed effect model was used in the meta-analysis of the pooled sample. The meta-analysis shows a significantly greater decrease in weight over the treatment period among patients receiving metformin than among those who did not receive metformin: the mean difference between the two groups was -2.89 kg (95% CI: -4.20 to -1.59 kg, *p*\<0.001).

![Figure 2. Forest plot of the meta-analysis of the effect of adjunctive treatment with metformin on the body weight (kg) of patients with schizophrenia being treated with clozapine](sap-27-06-331-g004){#Figure2}

[Figure 3](#Figure3){ref-type="fig"} shows the Forest plot of the results of the meta-analysis of the four studies with a pooled sample of 265 individuals that compared changes in BMI after adjunctive treatment with metformin.\[[@B7],[@B24],[@B26],[@B27]\] The results of these studies were quite homogeneous (*I*^2^=0% and *p*=0.83) so a fixed effect model was used in the pooled meta-analysis. The results indicate a significantly greater decrease in BMI over the course of treatment among patients who received metformin than in those who did not receive metformin: the mean difference in the change in BMI between groups was -0.81 (95% CI: -1.16 to -0.45, *p*\<0.001).

![Figure 3. Forest plot of the meta-analysis of the effect of adjunctive treatment with metformin on the body mass index (BMI) of patients with schizophrenia being treated with clozapine](sap-27-06-331-g005){#Figure3}

As shown in [Table 3](#Table3){ref-type="table"} , based on the GRADE measure, the strength of the evidence supporting the finding about reduction of clozapine-induced weight gain with adjunctive metformin treatment was classified as \'moderate\' and the strength of the evidence supporting the finding about reduction in the clozapine-induced rise in BMI with adjunctive metformin treatment was classified as \'high\'.

###### 

Table 3. Cochrane Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)\[[@B20]\] assessment of strength of evidence

Table 3.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Outcome measure     number\       heterogeneity   model of\   total effects   measure\   95% CI        GRADE\                     
                      of studies\                   analysis                    compared                 result                     
                      (pooled\                                                                                                      
                      sample)                                                                                                       
  ------------------- ------------- --------------- ----------- --------------- ---------- ------------- ----------- -------------- ----------
  Weight              5(341)        40%             0.16        fixed effect    **4.35**   **\<0.001**   MD=-2.89    -4.20, -1.59   moderate

  Body Mass Index\    4(265)        0%              0.83        fixed effect    **4.5**    **\<0.001**   MD=-0.81    -1.16, -0.45   high
  (BMI)                                                                                                                             

  Treatment effect    3(146)        40%             0.19        fixed effect    1.36       0.17          SMD=-0.23   -0.56, 0.10    high

  Dropout rate        3(241)        59%             0.09        random\         0.4        0.69          RR=1.48     0.21, 10.30    moderate
                                                                effects                                                             

  Any side effects    2(172)        0%              0.75        fixed effect    0          1             RR=1.00     0.77, 1.30     low

  constipation        2(172)        0%              1           fixed effect    0.43       0.67          RR=0.86     0.42, 1.74     low

  sinus tachycardia   2(172)        0%              0.76        fixed effect    0.26       0.8           RR=1.13     0.46, 2.78     low

  weakness            2(172)        0%              0.6         fixed effect    0          1             RR=1.00     0.39, 2.54     low

  ALT elevation       2(172)        0%              0.93        fixed effect    0.86       0.39          RR=1.60     0.55, 4.69     low

  orthostatic\        2(172)        0%              0.67        fixed effect    0.72       0.47          RR=0.60     0.15, 2.43     low
  hypotension                                                                                                                       

  nausea              2(172)        0%              0.85        fixed effect    0.72       0.47          RR=1.67     0.41, 6.67     low

  dry mouth           1(72)         N/A             N/A         fixed effect    0.46       0.65          RR=0.67     0.12, 3.75     very low

  hypersomnia         1(72)         N/A             N/A         fixed effect    0.58       0.56          RR=0.50     0.05, 5.27     very low
  --------------------------------------------------------------------------------------------------------------------------------------------

3.4 Secondary results {#s8d}
=====================

As shown in [Table 3](#Table3){ref-type="table"} , three of the RCTs\[[@B7],[@B24],[@B26]\] compared the treatment effect (based on changes in BPRS or PANSS scores) in the intervention and control groups. The results of the three studies were reasonably homogenous (*I*^2^=40% and *p*=0.19) so a fixed effect model meta-analysis of the pooled results was conducted. The standardized mean difference (SMD) between the intervention and control conditions favored the metformin group (i.e., the treatment outcome was better), but the difference was not large enough to be statistically significant: the SMD between the two groups was -0.23 (95% CI: -0.56 to 0.10, *p*=0.17). The quality of the evidence for this outcome was classified as \'high\'.

Only three of the studies\[[@B7],[@B26],[@B27]\] provided numbers of dropouts. A total of 31 (12.9%) dropouts occurred among the 241 individuals in the pooled sample from these three studies; the dropout rate in the pooled intervention group was 14.9% (18/121) and that in the pooled control group was 10.8% (13/120). The differences in the dropout rates between the intervention group and control group across the three studies were quite different (*I*^2^=59% and *p*=0.09), so a random effects model was used in the meta-analysis of the pooled sample. The result of the meta-analysis indicates that the difference in the dropout rate between the intervention group patients and control group patients was not statistically significant (RR=1.48, 95% CI: 0.21 to 10.30, *p*=0.69). The quality of the evidence for this outcome was classified as \'moderate\'.

Only two studies with a pooled sample of 172 individuals (86 in each group) provided comparative data on side effects between the intervention and control groups.\[[@B25],[@B26]\] A total of 96 separate episodes of side effects were reported in these two studies, 48 events in the pooled metformin group and 48 events in the pooled control group. The prevalence of the specific side effects in the two groups (in order of overall prevalence in the combined pooled sample) were as follows: constipation (14.0% in the intervention group v. 16.3% in the control group), tachycardia (10.5% v. 9.3%), weakness (9.3% v. 9.3%), elevated alanine aminotransferase (9.3% v. 5.8%), hypotension (3.5% v. 5.8%), nausea (5.8% v. 3.5%), dry mouth (5.6% v. 8.3% \[only assessed in one study\[[@B27]\]\]), and hypersomnia (2.8% v. 5.6% \[only assessed in one study\[[@B27]\]\]). As shown in [Table 3](#Table3){ref-type="table"} , meta-analysis of the pooled results found no statistically significant differences in the occurrence of these side effects between the intervention and control group. However, the data on side effects from these two studies was based on spontaneous patient reports and on routine laboratory tests and electrocardiograms - not on the regular administration of a standardized scale to assess side effects - so the quality of evidence supporting this conclusion about the relative safety of adjunctive treatment with metformin was classified as \'low\' or \'very low\'.

4.Discussion {#s9}
============

4.1 Main findings {#s9a}
=================

This meta-analysis finds that adjunctive treatment with metformin is effective in reducing clozapine-induced weight gain and clozapine-induced elevations in BMI. The mean difference in the change in weight over the treatment period between patients who do and do not receive adjunctive metformin (2.89 kg) is similar to the weight change reported in previous studies in China of adjunctive metformin treatment for olanzapine-induced weight gain\[[@B29]\] (3.6 kg) and of adjunctive metformin treatment for weight gain associated with the use of atypical antipsychotic medications\[[@B30]\] (3.1 kg). This result parallels that of a meta-analysis of 21 RCTs which assessed the effectiveness of metformin in reducing the weight gain induced by a wide variety of antipsychotic medications (including aripiprazole, clozapine, olanzapine, quetiapine, chloropromazine, risperidone and sulpiride).\[[@B31]\]

The proposed mechanisms of action of metformin that could result in reduced weight gain include: (a) activation of adenosine monophosphate (AMP) and protein kinases that suppress dysplasia of hepatic gluconeogenesis and the synthesis of lipids; (b) suppression of cells in the gastrointestinal wall that uptake glucose; and (c) an increase in insulin sensitivity.\[[@B25]\] There are also other agents that appear to have similar effects. For example, topiramate (an anticonvulsant drug) has been reported to be effective in the treatment of clozapine-induced weight gain in patients with schizophrenia.\[[@B32],[@B33]\] More work is needed to clarify the mechanism of action (and potential negative effects) of these agents before they can be confidently recommended as standard adjunctive treatments in patients receiving long-term antipsychotic treatment. Moreover, most studies indicate that the risk profile for metabolic changes differs for different antipsychotic medications, so it is reasonable to assume that the effectiveness and mechanism of action of metformin and other agents in reducing these negative effects will vary depending on the type of antipsychotic medication being used. Future studies need to include more detailed comparisons of the effectiveness of adjunctive treatments for different types of antipsychotic medications.

4.2 Limitations {#s9b}
===============

Several limitations need to be considered. (a) We only located 6 relevant RCTs, all of which were single-center studies with relatively small sample sizes (55 to 100 individuals), so the representativeness of the results for all patients with schizophrenia treated with clozapine is uncertain. And, given the small number of studies, it was not possible to assess publication bias. (b) Three of the six studies did not use placebo controls and, thus, the patients, clinicians, and evaluators were not blind to the group assignment of the patients. The main outcomes of interest (weight change and change in BMI) were fairly objective measures and the strength of the evidence for these results were classified as \'moderate\' and \'high\'; nevertheless, this lack of blinding could lead to biased reporting. (c) Only two of the six studies provided data on side effects and the quality of this evidence (which was not collected using standardized instruments) was classified as \'low\' or \'very low\', so it is impossible to determine whether or not adjunctive treatment with metformin increases the prevalence of side-effects in patients receiving clozapine. (d) Related studies\[[@B8]\] suggest that some of the beneficial effects of adjunctive metformin treatment in patients receiving antipsychotic medications do not occur until after 24 weeks of treatment, so the relatively short followup periods in the included studies may have led to an underestimate of the benefits of metformin. (e) Weight gain and increased BMI are the final outcome of a variety of metabolic changes related to dyslipidemia and insulin resistance. Effective use of adjunctive treatment with metformin (i.e., targeting the treatment on the most susceptible patients and determining the correct dosage and duration of treatment) will require more detailed assessment of the underlying mechanisms affecting metabolic changes in patients receiving antipsychotic medication and, importantly, the biochemical role metformin plays in halting or reversing these negative metabolic outcomes.

4.3 Importance {#s9c}
==============

The present study pooled results from 3 RCTs published in English and 3 RCTs published in Chinese to assess the effectiveness of metformin in reducing clozapine-induced weight gain and clozapine-induced increases in BMI among adult patients with schizophrenia. The meta-analysis confirms the results of previous studies indicating that metformin is, indeed, effective in reducing antipsychotic-induced weight gain and increased BMI, and the quality of the evidence for these two outcomes was rated as \'moderate\' and \'high\', respectively. But the six included studies followed patients for relatively short periods (6 to 24 weeks) and they did not include a comprehensive assessment of potential side-effects that could complicate the long-term use of metformin as an adjunctive treatment with clozapine. Larger studies that are placebo controlled, that use double blind assessment of outcomes, that follow patients for much longer periods of time (up to 1 year), that include standardized assessments of the full range of potential side effects, and that include a wider range of outcome measures (including measures of dyslipidemia and insulin resistance) are needed before adjunctive metformin can be included in the standard treatment regimens of patients receiving long-term treatment with clozapine or other antipsychotic medications.
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